ArticleMovement disorders clinical practice2026
Artificial Intelligence Predicts GBA1 Mutated Status in Parkinson's Disease Patients.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dual impact of GBA1 in disease: from germline mutations in neurological disorders to alterations in cancer.Cell death discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
backgroundGBA1 variants are the major genetic risk factor for Parkinson's Disease (PD) and account for 5-30% of PD cases depending on the population and age at onset of the disease.
objectivesThe aim of this study was to assess whether Artificial Intelligence (AI) could predict GBA1-mutated genotype in PD (GBA1-PD). Particularly, the main objective was to identify a Machine Learning (ML) model capable of accurately providing a pre-test estimate of GBA1-mutated status, relying on the clinical and demographic variables with the highest predictive value.
methodsA cohort of GBA1-PD patients has been paired with non-mutated PD (NM-PD). The dataset comprised 58 GBA1-PD and 58 NM-PD, for each of whom 124 features were recorded. A Leave-One-Out cross-validation method was employed for testing and SHapley Additive exPlanations (SHAP) for examine each feature's contribution. XGBoost resulted the most effective ML model for this supervised classification task.
resultsThrough AI, we developed a model based on four specific clinical features with significant impact in predicting GBA1-mutated genotype with an accuracy of 73%, reaching 94% in a subset of patients where the model has a SHAP confidence level greater than 80%. These variables included family history and scores for cognitive (MDS-UPDRS 1.1) and motor impairment (MDS-UPDRS 3.8a and 3.8b and rigidity subscore).
conclusionsThis study underlies the potential of AI in enhancing targeted genetic screening in PD, especially in clinical settings where resources are limited. Main limitations of this study are the modest sample size and lack of external validation. Further studies on larger, independent cohorts are needed to refine the predictive model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.